{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban%2C+%28BAY59-7939%29",
    "query": {
      "intervention": "Rivaroxaban, (BAY59-7939)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban%2C+%28BAY59-7939%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T03:15:07.252Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02504216",
      "title": "Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Peripheral Artery Disease"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban-Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 6564,
      "start_date": "2015-08-18",
      "completion_date": "2020-01-09",
      "has_results": true,
      "last_update_posted_date": "2020-12-08",
      "last_synced_at": "2026-10-06T03:15:07.252Z",
      "location_count": 105,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fort Payne",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Avondale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02504216"
    },
    {
      "nct_id": "NCT01145859",
      "title": "Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Venous Thrombosis",
        "Pediatrics"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 59,
      "start_date": "2010-11",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-08-06",
      "last_synced_at": "2026-10-06T03:15:07.252Z",
      "location_count": 16,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Orange, California + 11 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01145859"
    },
    {
      "nct_id": "NCT02309411",
      "title": "EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "6 Months to 5 Years"
      },
      "enrollment_count": 46,
      "start_date": "2015-01-15",
      "completion_date": "2017-04-05",
      "has_results": true,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-10-06T03:15:07.252Z",
      "location_count": 5,
      "location_summary": "Gainesville, Florida • Pensacola, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02309411"
    },
    {
      "nct_id": "NCT00439777",
      "title": "Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin overlapping with and followed by VKA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4833,
      "start_date": "2007-03",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2014-02-27",
      "last_synced_at": "2026-10-06T03:15:07.252Z",
      "location_count": 23,
      "location_summary": "Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00439777"
    },
    {
      "nct_id": "NCT03214172",
      "title": "Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2017-07-15",
      "completion_date": "2017-09-15",
      "has_results": false,
      "last_update_posted_date": "2018-09-06",
      "last_synced_at": "2026-10-06T03:15:07.252Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03214172"
    },
    {
      "nct_id": "NCT00440193",
      "title": "Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin followed by VKA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3449,
      "start_date": "2007-03",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2014-02-27",
      "last_synced_at": "2026-10-06T03:15:07.252Z",
      "location_count": 23,
      "location_summary": "Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00440193"
    },
    {
      "nct_id": "NCT02497716",
      "title": "Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Thrombosis"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Months to 12 Years"
      },
      "enrollment_count": 47,
      "start_date": "2015-11-04",
      "completion_date": "2018-05-22",
      "has_results": false,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-10-06T03:15:07.252Z",
      "location_count": 5,
      "location_summary": "Little Rock, Arkansas • Oakland, California • Indianapolis, Indiana + 2 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02497716"
    },
    {
      "nct_id": "NCT03374540",
      "title": "Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Nonvalvular Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Vitamin K antagonist (VKA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78517,
      "start_date": "2017-12-01",
      "completion_date": "2019-08-30",
      "has_results": false,
      "last_update_posted_date": "2020-08-17",
      "last_synced_at": "2026-10-06T03:15:07.252Z",
      "location_count": 1,
      "location_summary": "Multiple Locations, Washington",
      "locations": [
        {
          "city": "Multiple Locations",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03374540"
    },
    {
      "nct_id": "NCT00402467",
      "title": "An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban, (BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 613,
      "start_date": "2004-02",
      "completion_date": "2004-11",
      "has_results": false,
      "last_update_posted_date": "2014-12-23",
      "last_synced_at": "2026-10-06T03:15:07.252Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402467"
    },
    {
      "nct_id": "NCT02234843",
      "title": "EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 500,
      "start_date": "2014-11-13",
      "completion_date": "2019-01-30",
      "has_results": true,
      "last_update_posted_date": "2020-04-01",
      "last_synced_at": "2026-10-06T03:15:07.252Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02234843"
    }
  ]
}